Table 1.
Type of Vaccine | Synthetic Long-Peptide Vaccine | DNA Vaccine | mRNA Vaccine | circRNA Vaccine |
---|---|---|---|---|
Synthesis | Synthetic long peptides | Plasmid DNA encoding the antigen | mRNA transcribed in vitro | CircRNA constructed in vitro |
Advantages | Stable Safe Easy to purify Long immunization time |
Stable (can be stored at room temperature) Simple production process Low cost Mass production |
Fast production Low cost Cytoplasmic translation No risk of genomic integration Self-adjuvant effect |
More stable and easy to store Cytoplasmic translation No risk of genomic integration Self-adjuvant effect High antigen expression efficiency |
Disadvantages | Complex in vitro synthesis High cost Low immune response Potential adverse effects |
Risk of genomic integration Must cross the nuclear membrane to be transcribed Carcinogenic risk |
Poor stability Easily degradable Harsh storage conditions High risk of side effects |
Currently not available for mass production Safety unknown |
Improvement program | Use immune adjuvants | Vector and promoter optimization Improve inoculation route |
Improvement of target gene expression Improve delivery system |
Nucleotide modifications Improve cyclization efficiency Improve purification methods |
Reference | [33,34,35] | [36,37] | [38,39,40] | [28,41,42,43] |